Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the , to be held from March 14-16, 2024, in Milan, Italy, and the , to be held from March 15-17, 2024, in Panama City, Panama. Details of the presentations are as follows:
3rd ITACA National Congress, Milan, Italy, March 14-16, 2024.
- Title: Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
Presenter: Mauro Cancian, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT) - Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Presenter: Giuseppe Spadaro, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT) - Title: Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
Presenter: Andrea Zanichelli, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT) - Title: Need for Caregiver Support for People Living With Hereditary Angioedema in European Countries
Presenter: Andrea Zanichelli, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT) - Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presenter: Mauro Cancian, M.D., Ph.D.
Format: Selected Oral and Poster Presentation
Date, time: Saturday, March 16, 10:00 a.m. CET (5:00 a.m. EDT)
2024 HAEi Regional Conference Americas, Panama City, Panama, March 15-17, 2024.
- Title: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
Presenter: Anete Grumach, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, March 15, 7:20 p.m. EDT - Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Presenter: Markus Magerl, M.D.
Format: Poster Presentation
Date, time: Friday, March 15, 7:20 p.m. EDT - Title: Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
Presenter: Marcus Maurer, M.D.
Format: Poster Presentation
Date, time: Friday, March 15, 7:20 p.m. EDT - Title: Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presenter: Marc A. Riedl, M.D., M.S.
Format: Oral Presentation
Date, time: Saturday, March 16, 9:30 a.m. EDT - Title: Understanding Patient Reasons not to Treat All Hereditary Angioedema (HAE) Attacks and Characteristics of Untreated HAE Attacks: Results from a Real World Survey
Presenter: William Lumry, M.D.
Format: Oral Presentation
Date, time: Saturday, March 16, 11:15 a.m. EDT
The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: .
About Pharvaris
Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit .
Contact
Maggie Beller
Executive Director, Head of External and Internal Communications
